Boston Scientific Class Action Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Should l Buy BSX?
Source: PRnewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Participants are not required to pay any upfront fees or costs, as the law firm will handle the case through a contingency fee arrangement, ensuring investors can seek compensation without financial burden.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, leading to investor losses when the company missed net income expectations, highlighting management's misjudgment of the electrophysiology segment's growth rate.
- Law Firm Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its success and resource advantages in handling such cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 62.590
Low
94.00
Averages
108.14
High
132.00
Current: 62.590
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Participants can receive compensation without any upfront costs through a contingency fee arrangement, which reduces the financial burden on investors and encourages more affected individuals to join the lawsuit.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, leading investors to misunderstand the growth prospects of its electrophysiology segment, ultimately resulting in a net income miss and investor losses.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and successful track record in handling such cases.
See More
Boston Scientific Stock Declines Amid Market Trends
- Stock Performance: Boston Scientific (BSX) ended the recent trading session at $61.86, reflecting a -1.17% change from the previous day, underperforming the S&P 500's 0.08% gain, indicating market caution regarding its short-term outlook.
- Monthly Decline: The stock has dropped by 12.95% over the past month, significantly exceeding the Medical sector's 6.98% decline, which may undermine investor confidence in the company's relative strength within the industry.
- Earnings Expectations: The upcoming earnings report, scheduled for April 22, 2026, is projected to reveal an EPS of $0.8, indicating a 6.67% growth year-over-year, with revenue expected at $5.19 billion, up 11.2% from the prior year, potentially providing price support.
- Analyst Ratings: Currently, BSX holds a Zacks Rank of #3 (Hold), with a recent 0.15% decline in EPS estimates; however, its forward P/E ratio of 18.13 is slightly below the industry average of 18.15, suggesting some investment value.
See More
Boston Scientific Faces Class Action Lawsuit
- Class Action Initiated: Pomerantz LLP has announced a class action lawsuit against Boston Scientific, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors advised to apply as Lead Plaintiff by May 4, 2026.
- Disappointing Earnings Report: Boston Scientific's Q4 2025 financial results, released on February 4, 2026, revealed lower-than-expected sales in its electrophysiology division and guidance for fiscal year 2026 that significantly missed analyst expectations, indicating challenges from slow market growth and increased competition.
- Significant Stock Decline: Following the earnings report, Boston Scientific's stock price plummeted by $16.12, or 17.6%, closing at $75.50 per share on February 4, 2026, reflecting market concerns regarding the company's future outlook.
- Legal Firm Background: Pomerantz LLP is a prominent firm in securities class litigation, established over 85 years ago, dedicated to fighting for the rights of victims of securities fraud and corporate misconduct, having recovered numerous multimillion-dollar damages for class members.
See More
Boston Scientific Faces Class Action Lawsuit from Shareholders
- Lawsuit Background: Boston Scientific Corporation is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims from investors who purchased shares between July 23, 2025, and February 3, 2026, asserting that the company and its executives made misleading statements affecting investor decisions.
- Investor Rights: Affected investors can apply to serve as lead plaintiff by May 4, 2026, representing other investors in the litigation, while those who choose not to participate can still share in any potential recovery without being lead plaintiffs.
- Legal Fee Arrangement: The lawsuit operates on a contingency fee basis, meaning investors incur no fees or expenses, significantly reducing the financial burden on investors wishing to participate in the legal action.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has extensive experience in handling hundreds of class actions, highlighting its strong reputation and capabilities in the legal field.
See More
Boston Scientific Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, to apply as lead plaintiffs by May 4, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the Class Period, concealing the true state of its U.S. Electrophysiology segment, which led to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, highlighting its successful track record, thus investors should choose experienced counsel wisely.
- Investor Action Steps: Investors can visit Rosen Law Firm's website or call the toll-free number for more information on joining the class action, noting that no class has been certified yet, allowing them to choose counsel or remain absent class members.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Boston Scientific Corporation is facing a class action lawsuit for alleged violations of federal securities laws, with plaintiffs being investors who purchased securities between July 23, 2025, and February 3, 2026, seeking to recover damages.
- False Statements Allegations: The complaint alleges that executives made materially false and misleading statements during the relevant period, failing to disclose that the growth rate of its U.S. electrophysiology segment was unsustainable, which undermined investor confidence in the company's future.
- Market Impact: The company is reportedly experiencing adverse trends such as declining procedure volumes and increasing competitive pressures, leading plaintiffs to argue that the executives' optimistic projections lacked a reasonable basis, potentially resulting in a stock price decline.
- Investor Actions: Affected investors must apply by May 4, 2026, to be appointed as lead plaintiffs to participate in any potential recovery, with the law firm promising to charge fees only upon success, thereby reducing the financial risk for investors.
See More
Boston Scientific Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Participants can receive compensation without any upfront costs through a contingency fee arrangement, which reduces the financial burden on investors and encourages more affected individuals to join the lawsuit.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, leading investors to misunderstand the growth prospects of its electrophysiology segment, ultimately resulting in a net income miss and investor losses.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and successful track record in handling such cases.
See More
Boston Scientific Stock Declines Amid Market Trends
- Stock Performance: Boston Scientific (BSX) ended the recent trading session at $61.86, reflecting a -1.17% change from the previous day, underperforming the S&P 500's 0.08% gain, indicating market caution regarding its short-term outlook.
- Monthly Decline: The stock has dropped by 12.95% over the past month, significantly exceeding the Medical sector's 6.98% decline, which may undermine investor confidence in the company's relative strength within the industry.
- Earnings Expectations: The upcoming earnings report, scheduled for April 22, 2026, is projected to reveal an EPS of $0.8, indicating a 6.67% growth year-over-year, with revenue expected at $5.19 billion, up 11.2% from the prior year, potentially providing price support.
- Analyst Ratings: Currently, BSX holds a Zacks Rank of #3 (Hold), with a recent 0.15% decline in EPS estimates; however, its forward P/E ratio of 18.13 is slightly below the industry average of 18.15, suggesting some investment value.
See More
Boston Scientific Faces Class Action Lawsuit
- Class Action Initiated: Pomerantz LLP has announced a class action lawsuit against Boston Scientific, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors advised to apply as Lead Plaintiff by May 4, 2026.
- Disappointing Earnings Report: Boston Scientific's Q4 2025 financial results, released on February 4, 2026, revealed lower-than-expected sales in its electrophysiology division and guidance for fiscal year 2026 that significantly missed analyst expectations, indicating challenges from slow market growth and increased competition.
- Significant Stock Decline: Following the earnings report, Boston Scientific's stock price plummeted by $16.12, or 17.6%, closing at $75.50 per share on February 4, 2026, reflecting market concerns regarding the company's future outlook.
- Legal Firm Background: Pomerantz LLP is a prominent firm in securities class litigation, established over 85 years ago, dedicated to fighting for the rights of victims of securities fraud and corporate misconduct, having recovered numerous multimillion-dollar damages for class members.
See More
Boston Scientific Faces Class Action Lawsuit from Shareholders
- Lawsuit Background: Boston Scientific Corporation is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims from investors who purchased shares between July 23, 2025, and February 3, 2026, asserting that the company and its executives made misleading statements affecting investor decisions.
- Investor Rights: Affected investors can apply to serve as lead plaintiff by May 4, 2026, representing other investors in the litigation, while those who choose not to participate can still share in any potential recovery without being lead plaintiffs.
- Legal Fee Arrangement: The lawsuit operates on a contingency fee basis, meaning investors incur no fees or expenses, significantly reducing the financial burden on investors wishing to participate in the legal action.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has extensive experience in handling hundreds of class actions, highlighting its strong reputation and capabilities in the legal field.
See More
Boston Scientific Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, to apply as lead plaintiffs by May 4, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the Class Period, concealing the true state of its U.S. Electrophysiology segment, which led to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, highlighting its successful track record, thus investors should choose experienced counsel wisely.
- Investor Action Steps: Investors can visit Rosen Law Firm's website or call the toll-free number for more information on joining the class action, noting that no class has been certified yet, allowing them to choose counsel or remain absent class members.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Boston Scientific Corporation is facing a class action lawsuit for alleged violations of federal securities laws, with plaintiffs being investors who purchased securities between July 23, 2025, and February 3, 2026, seeking to recover damages.
- False Statements Allegations: The complaint alleges that executives made materially false and misleading statements during the relevant period, failing to disclose that the growth rate of its U.S. electrophysiology segment was unsustainable, which undermined investor confidence in the company's future.
- Market Impact: The company is reportedly experiencing adverse trends such as declining procedure volumes and increasing competitive pressures, leading plaintiffs to argue that the executives' optimistic projections lacked a reasonable basis, potentially resulting in a stock price decline.
- Investor Actions: Affected investors must apply by May 4, 2026, to be appointed as lead plaintiffs to participate in any potential recovery, with the law firm promising to charge fees only upon success, thereby reducing the financial risk for investors.
See More
